Antibody Response After the Third SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients and People Living With HIV (COVERALL-2)

Author:

Griessbach Alexandra1,Chammartin Frédérique1ORCID,Abela Irene A23,Amico Patrizia4,Stoeckle Marcel P5,Eichenberger Anna L6,Hasse Barbara3,Braun Dominique L23,Schuurmans Macé M7,Müller Thomas F8,Tamm Michael9,Audigé Annette2,Mueller Nicolas J4,Rauch Andri6,Günthard Huldrych F23,Koller Michael T410,Trkola Alexandra2ORCID,Epp Selina2,Amstutz Alain1,Schönenberger Christof M1,Taji Heravi Ala1,Papadimitriou-Olivgeris Matthaios11,Casutt Alessio12,Manuel Oriol11ORCID,Kusejko Katharina23ORCID,Bucher Heiner C15,Briel Matthias113ORCID,Speich Benjamin1ORCID,I Abela,K Aebi-Popp,A Anagnostopoulos,M Battegay,E Bernasconi,DL Braun,HC Bucher,A Calmy,M Cavassini,A Ciuffi,G Dollenmaier,M Egger,L Elzi,J Fehr,J Fellay,H Furrer,CA Fux,HF Günthard,A Hachfeld,D Haerry,B Hasse,HH Hirsch,M Hoffmann,I Hösli,M Huber,D Jackson-Perry,CR Kahlert,L Kaiser,O Keiser,T Klimkait,RD Kouyos,H Kovari,K Kusejko,N Labhardt,K Leuzinger,de Tejada B Martinez,C Marzolini,KJ Metzner,N Müller,J Nemeth,D Nicca,J Notter,P Paioni,G Pantaleo,M Perreau,A Rauch,L Salazar-Vizcaya,P Schmid,R Speck,M Stöckle,P Tarr,A Trkola,G Wandeler,M Weisser,S Yerly,Amico Patrizia,Aubert John-David,Banz Vanessa,Beckmann Sonja,Beldi Guido,Berger Christoph,Berishvili Ekaterine,Berzigotti Annalisa,Binet Isabelle,Bochud Pierre-Yves,Branca Sanda,Bucher Heiner,Catana Emmanuelle,Cairoli Anne,Chalandon Yves,De Geest Sabina,De Rougemont Olivier,De Seigneux Sophie,Dickenmann Michael,Dreifuss Joëlle Lynn,Duchosal Michel,Fehr Thomas,Ferrari-Lacraz Sylvie,Garzoni Christian,Golshayan Déla,Goossens Nicolas,Haidar Fadi,Halter Jörg,Heim Dominik,Hess Christoph,Hillinger Sven,Hirsch Hans H,Hirt Patricia,Hoessly Linard,Hofbauer Günther,Huynh-Do Uyen,Immer Franz,Koller Michael,Laesser Bettina,Lamoth Frédéric,Lehmann Roger,Leichtle Alexander,Manuel Oriol,Marti Hans-Peter,Martinelli Michele,McLin Valérie,Mellac Katell,Merçay Aurélia,Mettler Karin,Mueller Nicolas J,Müller-Arndt Ulrike,Müllhaupt Beat,Nägeli Mirjam,Oldani Graziano,Pascual Manuel,Passweg Jakob,Pazeller Rosemarie,Posfay-Barbe Klara,Rick Juliane,Rosselet Anne,Rossi Simona,Rothlin Silvia,Ruschitzka Frank,Schachtner Thomas,Schaub Stefan,Scherrer Alexandra,Schnyder Aurelia,Schuurmans Macé,Schwab Simon,Sengstag Thierry,Simonetta Federico,Stampf Susanne,Steiger Jürg,Stirnimann Guido,Stürzinger Ueli,Van Delden Christian,Venetz Jean-Pierre,Villard Jean,Vionnet Julien,Wick Madeleine,Wilhelm Markus,Yerly Patrick,

Affiliation:

1. Division of Clinical Epidemiology, Department of Clinical Research, University Hospital Basel, University of Basel , Basel , Switzerland

2. Institute of Medical Virology, University of Zurich , Zurich , Switzerland

3. Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich , Zurich , Switzerland

4. Clinic for Transplantation Immunology and Nephrology, University Hospital Basel , Basel , Switzerland

5. Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, University of Basel , Basel , Switzerland

6. Department of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern , Bern , Switzerland

7. Division of Pulmonology, University Hospital Zurich , Zurich , Switzerland

8. Nephrology Clinic, University Hospital Zurich , Zurich , Switzerland

9. Clinic of Respiratory Medicine and Pulmonary Cell Research, University Hospital Basel , Basel , Switzerland

10. Swiss Transplant Cohort Study, University Hospital Basel , Basel , Switzerland

11. Infectious Diseases Service and Transplantation Center, Lausanne University Hospital , Lausanne , Switzerland

12. Division of Pulmonology, Department of Medicine, University Hospital of Lausanne , Lausanne , Switzerland

13. Department of Health Research Methods, Evidence, and Impact, McMaster University , Hamilton, Ontario , Canada

Abstract

Abstract Background After basic immunization with 2 mRNA SARS-CoV-2 vaccine doses, only a small proportion of patients who are severely immunocompromised generate a sufficient antibody response. Hence, we assessed the additional benefit of a third SARS-CoV-2 vaccine in patients with different levels of immunosuppression. Methods In this observational extension of the COVERALL trial (Corona Vaccine Trial Platform), we recruited patients from the Swiss HIV Cohort Study and the Swiss Transplant Cohort Study (ie, lung and kidney transplant recipients). We collected blood samples before and 8 weeks after the third SARS-CoV-2 vaccination with either mRNA-1273 (Moderna) or BNT162b2 (Pfizer-BioNTech). The primary outcome was the proportion of participants showing an antibody response (Elecsys Anti-SARS-CoV-2 S test; threshold ≥100 U/mL) 8 weeks after the third SARS-CoV-2 vaccination. We also compared the proportion of patients who reached the primary outcome from basic immunization (the first and second vaccines) to the third vaccination. Results Nearly all participants (97.2% [95% CI, 95.9%–98.6%], 564/580) had an antibody response. This response was comparable between mRNA-1273 (96.1% [95% CI, 93.7%–98.6%], 245/255) and BNT162b2 (98.2% [95% CI, 96.7%–99.6%], 319/325). Stratification by cohort showed that 99.8% (502/503) of people living with HIV and 80.5% (62/77) of recipients of solid organ transplants achieved the primary endpoint. The proportion of patients with an antibody response in solid organ transplant recipients improved from the second vaccination (22.7%, 15/66) to the third (80.5%, 62/77). Conclusions People living with HIV had a high antibody response. The third vaccine increased the proportion of solid organ transplant recipients with an antibody response. Clinical Trials Registration. NCT04805125 (ClinicalTrials.gov).

Funder

Moderna

Swiss National Science Foundation

University of Zurich Foundation

Promedica Foundation

University of Basel

Janggen Pöhn Foundation

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Oncology

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3